09:58 AM EDT, 05/28/2026 (MT Newswires) -- Medicenna Therapeutics ( MDNAF ) closed its previously announced marketed public offering of units at $0.50 apiece, for about $4.44 million, before deducting offering expenses and excluding any proceeds the company may receive from the exercise of the underlying warrants, it said on Thursday.

The raising will be used to support lead programs, it added.

Under the offering, MDNA issued a total of near 8.9-million units. Each unit is comprised of one common share and one-half of one common share purchase warrant of the company. Each warrant entitles the holder thereof to buy a share for $0.65 per warrant share until the date that is three years following the initial closing date of the offering.

The company also entered into a separate structured financing of $8.0 million with Sorbie Bornholm LP and Sorbie Investments LLP.

Shares of the company were last seen up 2.4% at $0.435 on the Toronto Stock Exchange.

Price: 0.44, Change: +0.01, Percent Change: +2.35